was determined using a Heλios β UV/VISspectrophotometer at λ 300 nm. Solvents were removed by rotary evaporation under reduced pressure at 40 °C. Melting points were determined using a Büchi melting point apparatus accordig to dr. Tottoli and were uncorrected.
sources and used without any further purification. Peptide grade or pro analysi solvents were purchased from Biosolve (Valkenswaard, the Netherlands) and dried on 4Å MS (MeOH: 3Å MS) before use. N,NDiisopropylethylamine (DIPEA) was distilled from ninhydrin and KOH-pellets. R f values were determined by thin layer chromatography (TLC) on Merck precoated silicagel 60F 254 plates. Spots were visualized with UV quenching, ninhydrin or with Cl 2 -TDM. 1 Solid phase peptide synthesis was monitored with the Kaiser test 2 and the loading of the resin 3 was determined using a Heλios β UV/VISspectrophotometer at λ 300 nm. Solvents were removed by rotary evaporation under reduced pressure at 40 °C. Melting points were determined using a Büchi melting point apparatus accordig to dr. Tottoli and were uncorrected. 
13
C NMR spectra were recorded using the attached proton test (APT) pulse sequence. Analytical HPLC runs were performed on a Shimadzu automated HPLC (SPD-10A VP) system equipped with an evaporative light scattering detector (PL-ELS 1000, Polymer Laboratories) and a UV/VIS detector operating at 220/254 nm. Preparative HPLC runs were performed on a Gilson HPLC workstation. Chiral HPLC analysis was performed on an analytical reverse-phase column (Astec, Teicoplanin, Chirobiotic T, 250 × 4.6 mm) at a steady flow of S2 0.5 mL/min with 1% TEA in H 2 O adjusted to pH 4 with AcOH/MeOH 1:1 v/v as eluens. Electrospray ionisation (ESI) mass spectrometry was carried out on a Shimadzu LCMS QP-8000 quadrupole benchtop spectrometer coupled to a QP-8000 data system. MS/MS-spectra were measured on a Micromass Quattro Ultima or a Micromass Q-TOF mass spectrometer.Optical rotations were measured on a Jasco P-1010 Polarimeter.
Solid phase peptide synthesis: Peptides 14 and 16 were synthesized manually on a 0.25 mmol scale on plain Argogel resin. Each synthetic cycle consisted of N-α-Fmoc removal by treatment with 20% piperidine in DMF (3 × 10 mL, 8 min), a washing step (DMF: 3 × 10 mL, 2 min; DCM: 3 × 10 mL, 2 min and DMF: 3 × 10 mL, 2 min) a coupling step (60 min) with 1.0 mmol of preactivated Fmoc amino acid in the presence of 2 equivalents DIPEA in DMF (10 mL) and a final washing step (DMF: 3 × 10 mL, 2 min; DCM: 3 × 10 mL, 2 min and DMF: 3 × 10 mL, 2 min). N-α-Fmoc amino acids (1 mmol) were activated in situ with BOP (1 mmol) in the presence of DIPEA (2 mmol). Fmoc-removal and coupling reactions were monitored by the Kaiser test. 2 The peptides were cleaved from the resin by treatment with a catalytic amount of KCN in MeOH (15 mL) during 16 h. The resin was filtered and washed with MeOH (3 × 10 mL), the filtrate was concentrated in vacuo to yield the crude peptide.
Solution phase peptide synthesis: Coupling reaction:
The carboxylic acid moiety (1 equiv) was coupled to the amine derivative (or its TFA-salt, 1 equiv) in the presence of BOP (1 equiv) and DIPEA (2 equiv, when the amine was protonated 3 equiv were used) as coupling reagents in DCM (10 mL per mmol) as solvent. Coupling time was 16 h. After completion of the reaction, DCM was removed under reduced pressure and the residue was dissolved in EtOAc (25 mL per mmol). The EtOAc solution was washed with 1N KHSO4 (3 × 25 mL), 10% Na 2 CO 3 (3 × 25 mL) and brine (1 × 25 mL), dried (Na 2 SO 4 ), filtrated and evaporated in vacuo. The obtained crude product was analyzed by TLC, 1 H NMR and ESI-MS and generally pure enough to be used in the next synthesis steps.
Boc-removal:
A Boc-protected intermediate was dissolved in TFA/DCM 1:1 v/v (4 mL per mmol) and stirred for 2 h. Then, the solvents were removed under reduced pressure and the residue was coevaporated with toluene (2 × 25 mL), CH 3 CN (2 × 25 mL) and DCM (2 × 25 mL) to remove any residual TFA. The obtained TFA-salt was used without further purification in the next synthesis steps. After the evaporation of the solvent the product was purified by column chromatography.
Alkylation of the Gly/Ni/BPB-complex with 1-Bromo-2-butyne: The Gly/Ni/BPB-complex 4, 5 (6 g, 12 mmol) and NaOH (1.2 g, 30 mmol) were dissolved in CH 3 CN (60 mL) and 1-bromo-2-butyne (1.2 mL, 13.4 mmol) was added dropwise. The deeply red mixture was stirred for 1.5 h at room temperature. Then, the excess of NaOH was neutralized with HCl (0.1 M, 180 mL). The alkylation product was extracted into CH 2 Cl 2 . The combined organic layers were dried (MgSO 4 ) and evaporated to dryness. The product was purified by silicagel column chromatography (eluens CHCl 3 /acetone 5:1 v/v) to obtain both diastereoisomers as red crystals with 61% yield (4 g 
S4
(S)-2-amino-5-hexynoic acid (H-Bug-OH) 1: The alkylated nickel-complex (10.1 g, 18.4 mmol) was dissolved in MeOH (300 mL) and heated till reflux. To this solution 2N HCl (200 mL) was added and the reaction mixture was refluxed. After 45 min the solvents were evaporated in vacuo. The green solid was dissolved in H 2 O and neutralized with concentrated ammonia until pH 9 was reached and subsequently concentrated to dryness. The obtained solid was washed with acetone to recover the chiral auxillary (5.8 g, 82%). After that, the remaining solid was suspended in H 2 O and centrifuged, the pellet was resuspended once and the insoluble material was collected by centrifugation. The obtained pellet was dried overnight in a vacuum dessicator to give 4.1 g of crude amino acid 1. The combined aqueous layers were evaporated to dryness and the residue was treated with a cation exchange resin (Dowex (RS)-N-(9-fluorenylmethyloxycarbonyl)-2-amino-5-hexynoic acid (Fmoc-Bug-OH) rac-4: To a suspension of K 2 CO 3 (836 mg, 6.03 mmol) in CH 3 CN (10 mL), tetrabutylammonium bromide (21 mg, 0.01 eq) followed by methyl N-(diphenylmethy1ene)-glycinate 6, 7 (508 mg, 2 mmol) were added. After stirring for 20 min, 1-bromo-2-butyne (186 _L, 2 mmol, 1 eq) was added dropwise and the reaction S5 mixture was refluxed overnight. After filtration and extensively washing of the remaining solids with diethyl ether, the organic layer was concentrated in vacuo. The product was redissolved in diethyl ether, and the organic phase was washed with H 2 O (2 × 25 mL). The organic layer was dried (MgSO 4 ) and evaporated to dryness. After purification by column chromatography using basic alumina (eluens:
EtOAc/hexanes 9:1 v/v) the alkylation product was obtained in 61% (372 mg). The imine was dissolved in diethyl ether (10 mL) and treated with 1M HCl (2.5 mL) for 3 h. The organic phase was separated and subsequently washed with H 2 O. The HCl solution and the combined H 2 O washings were concentrated to dryness and the residue was crystallized from MeOH/EtOAc to give 170 mg (84%) of racemic HCl.H-Bug-OH. Fmoc protection of the amino group was carried out as described for 4, yield:
71%.
Boc-Bug-Ile-Ala-Leu-Bug-OMe 6: Coupling and Boc-removal were carried out as described in the general procedure solution phase peptide synthesis. 
HCl.H-Bug-OMe
, 1.77 (m, 1H, CγH), 1.54 (m, 1H, CγH), 1.43 (s, 9H, Boc), 0.85-0.91 (m, 6H, Cγ'H/C_H); Ala:
S7
Boc-Pro-Gly-OMe: Yield: 592 mg (90%); R f (DCM/MeOH 9:1 v/v): 0. The protected dipeptide (300 mg, 1.1 mmol) was treated with TFA/DCM 1:1 v/v (4 mL) for 2 h to remove the Boc group. Then, the reaction mixture was concentrated in vacuo and coevaporated with toluene (2 × 10 mL), CH 3 CN (2 × 10 mL) and DCM (2 × 10 mL) to remove any residual TFA. The TFA-salt was dissolved in DCM (15 mL) and to this solution were added: Boc-Bug-OH (228 mg, 1.0 mmol), BOP (442 mg, 1.0 mmol) and DiPEA (436 µL, 2.5 mmol) and the obtained reaction mixture was stirred overnight. After evaporation of DCM, the residue was dissolved in EtOAc (50 mL) and this solution was washed with 1N KHSO 4 (3 × 20 mL), 10% Na 2 CO 3 (3 × 20 mL) and brine (1 × 20 mL), dried (Na 2 SO 4 ), filtrated and evaporated in vacuo. 31 and 8.80 (s, 1H, NH), 3.93-4.05 (m, 2H, C_H) 60 (d, 1H, NH 45 (bs, 1H, NH 
Boc-Bug-Pro-Gly-OMe

